The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-70 years old.
From a randomized trial, proof that the Novavax booster induces less acute side effects and more sustained levels of anti-spike IgG antibodies than mRNA shots